661 related articles for article (PubMed ID: 19837762)
21. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
[TBL] [Abstract][Full Text] [Related]
22. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
[TBL] [Abstract][Full Text] [Related]
23. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
[TBL] [Abstract][Full Text] [Related]
24. Dosimetry Assessment of Injected 89Zr-Labeled Monoclonal Antibodies in Humans.
Zakaly HMH; Mostafa MYA; Zhukovsky M
Radiat Res; 2019 May; 191(5):466-474. PubMed ID: 30896281
[TBL] [Abstract][Full Text] [Related]
25. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats.
Brouwers A; Verel I; Van Eerd J; Visser G; Steffens M; Oosterwijk E; Corstens F; Oyen W; Van Dongen G; Boerman O
Cancer Biother Radiopharm; 2004 Apr; 19(2):155-63. PubMed ID: 15186595
[TBL] [Abstract][Full Text] [Related]
26. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
[TBL] [Abstract][Full Text] [Related]
27. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
28. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study.
Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA
Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627
[TBL] [Abstract][Full Text] [Related]
29. First Evaluation of PET-Based Human Biodistribution and Dosimetry of
Savi A; Incerti E; Fallanca F; Bettinardi V; Rossetti F; Monterisi C; Compierchio A; Negri G; Zannini P; Gianolli L; Picchio M
J Nucl Med; 2017 Aug; 58(8):1224-1229. PubMed ID: 28209906
[No Abstract] [Full Text] [Related]
30. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
31. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
32. Preliminary results of biodistribution and dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
[TBL] [Abstract][Full Text] [Related]
33. Radiation Dosimetry and Biodistribution of
Meyer C; Dahlbom M; Lindner T; Vauclin S; Mona C; Slavik R; Czernin J; Haberkorn U; Calais J
J Nucl Med; 2020 Aug; 61(8):1171-1177. PubMed ID: 31836685
[TBL] [Abstract][Full Text] [Related]
34. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
[TBL] [Abstract][Full Text] [Related]
35. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
[TBL] [Abstract][Full Text] [Related]
36. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
37. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest.
Maddahi J; Czernin J; Lazewatsky J; Huang SC; Dahlbom M; Schelbert H; Sparks R; Ehlgen A; Crane P; Zhu Q; Devine M; Phelps M
J Nucl Med; 2011 Sep; 52(9):1490-8. PubMed ID: 21849402
[TBL] [Abstract][Full Text] [Related]
38. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
39. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer.
Zanzonico PB; Finn R; Pentlow KS; Erdi Y; Beattie B; Akhurst T; Squire O; Morris M; Scher H; McCarthy T; Welch M; Larson SM; Humm JL
J Nucl Med; 2004 Nov; 45(11):1966-71. PubMed ID: 15534070
[TBL] [Abstract][Full Text] [Related]
40. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]